<DOC>
	<DOCNO>NCT00756665</DOCNO>
	<brief_summary>The Prostate Active Surveillance Study ( PASS ) research study men choose active surveillance management plan prostate cancer . Active surveillance define close monitoring prostate cancer offer treatment change test result . This study seek discover marker identify cancer aggressive tumor grow slowly .</brief_summary>
	<brief_title>Prostate Active Surveillance Study</brief_title>
	<detailed_description>This multi-center , prospective active surveillance study selective intervention patient previously untreated , clinically localized prostate cancer diagnosis . Candidates assess base extend core biopsy , serum PSA ( include PSA kinetics , available ) , digital rectal examination ( DRE ) , assessment cancer grade extent . Active surveillance define serial PSA measurement prostate examination routine prostate biopsy therapeutic intervention consider time one following : - Grade volume progression - Clinical progression The objective study follow : Primary Objective â€¢ To discover confirm biomarkers predict aggressive disease define pre-specified histological , PSA , clinical criterion , outcome base variable . Secondary Objectives - To determine proportion patient active surveillance progress base criterion . - To determine clinical predictor disease progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate . Clinically localized prostate cancer : T12 , NX N0 , MX M0 . No previous treatment prostate cancer ( include hormonal therapy , radiation therapy , surgery , chemotherapy ) . ECOG Performance Status 0 1 . Patient elect Active Surveillance prefer management plan prostate cancer . Patient consent obtain accord local Institutional Review Board acquisition research specimens . Patient accessible compliant followup . Prostate biopsy requirement : 1 . If diagnosis within one year baseline visit , participant must least one biopsy least 10 core . 2 . If diagnosis 1 year prior baseline visit , participant must minimum 2 biopsy , one must within 2 year prior baseline visit . Unwillingness inability undergo serial prostate biopsy . History malignancy , except : adequately treat nonmelanoma skin cancer adequately treat superficial bladder cancer ( Ta ) solid tumor curatively treat evidence disease &gt; 5 year .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
</DOC>